Clinical trials: Nontuberculous Mycobacterium Infection
Cystic Fibrosis
Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis
The purpose of this study is to determine antimycobacterial drug pharmacokinetics (PK) and pharmacodynamics (PD) in patients with cystic fibrosis (CF) to improve treatment of nontuberculous mycobacterial (NTM) lung disease.
- Trial name
- NCT02372383
- Testing
- Ethambutol, Rifampin, Azithromycin
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Mycobacterium Avium-Intracellulare Infection
Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection
Mycobacterium avium complex (MAC) are ubiquitous organisms that cause isolated pulmonary disease in otherwise healthy patients with yet undefined susceptibilities.
- Trial name
- NCT00111397
- Testing
- Cytokine therapy, Interferon Gamma, GM-CSF
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Non-tuberculous Mycobacterial Infections
Linezolid for Treatment of Nontuberculous Mycobacterial Diseases
A prospective open study to determine the efficacy and tolerability of oral linezolid 600mg./day for the treatment of 40 patients with nontuberculous mycobacterial diseases will be conducted at Siriraj Hospital, Mahidol…
- Trial name
- NCT03220074
- Testing
- Oral Tablet
- Where
- Thailand
- Volunteers
- 40 people
- Sponsor
- Mahidol University
Rate of Exit Site Infection, Rate of Atypical Mycobacterial Infection
Topical Gentamicin Cream Versus Alternating Gentamicin and Mupirocin Cream in Peritoneal Dialysis
Catheter-related infection, namely exit site infection and peritonitis, is the commonest complication of peritoneal dialysis. This complication causes significant morbidity and mortality in patients requiring peritoneal dialysis.
- Conditions
- Rate of Exit Site Infection, Rate of Atypical Mycobacterial Infection, Rate of Peritoneal Dialysis
- Trial name
- NCT00751374
- Testing
- gentamicin, gentamicin cream alternating with mupirocin cream
- Where
- Hong Kong
- Volunteers
- 500 people
- Sponsor
- Kwong Wah Hospital
Nontuberculous Mycobacterial Infection
Sildenafil for PNTM Infection
Background: Pulmonary nontuberculous mycobacterial (PNTM) infection is caused by a common type of bacteria in the environment. Although PNTM infection is most common in people with lung diseases, it can also affect healthy…
- Trial name
- NCT01853540
- Testing
- Sildenafil
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease
The proposed study will assess the efficacy, safety and tolerability of once daily dosing of Liposomal-Amikacin for Inhalation (LAI) 590 mg for 12 months plus standard of care (SOC) mycobacterial multi-drug regimen in accordance…
- Trial name
- NCT03038178
- Testing
- LAI plus multi-drug regimen
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Kevin Winthrop
Mycobacterium Avium Complex
A Study of Standard Drugs for Mycobacterium Avium Complex
To assess the early bactericidal activity of Azithromycin 250mg by mouth daily over the first 14 days of treatment for Mycobacterium avium complex (MAC) lung disease.
- Trial name
- NCT04287049
- Testing
- Azithromycin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Leprosy
Ciclosporin in the Management of New Erythema Nodosum Leprosum
Study 2A: Ciclosporin in the management of new Erythema Nodosum Leprosum Objective: A pilot (double blind controlled) study randomizing patients to treatment either with Ciclosporin or Prednisolone to assess the safety…
- Trial name
- NCT00919542
- Testing
- Ciclosporin, prednisolone
- Where
- Ethiopia
- Volunteers
- 12 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Hansen's Disease
Epidemiology of Leprosy in French Guiana
The main objective of the present study is the genotyping of M. leprae strains found in leprosy patients in French Guiana. The secondary objectives are to investigate the presence of M.
- Trial name
- EPI-LEPR (NCT05031091)
- Testing
- standardised exposure questionnaire
- Where
- French Guiana
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Leprosy, Mycobacterium Leprae Infection
Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients
Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the…
- Trial name
- NCT06819449
- Testing
- Dapsone
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- South Valley University
Nontuberculous Mycobacterial Lung Disease, Bronchiectasis
Hypertonic Saline Inhalation for Nontuberculous Mycobacterial Lung Disease
This multicenter randomized controlled trial evaluates the clinical and microbiological effects of inhaled 3% hypertonic saline in treatment-naïve patients with nontuberculous mycobacterial lung disease (NTM-LD).
- Trial name
- HiNTM (NCT07647575)
- Testing
- Nebulized 3% Hypertonic Saline, Nebulized Normal Saline
- Where
- Taiwan
- Volunteers
- 262 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Cystic Fibrosis
Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus
To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M.
- Trial name
- NOMAB (NCT05101915)
- Testing
- RESP301
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Papworth Hospital NHS Foundation Trust